Clinical Trial

Expiratory Muscle Training in Parkinson's Disease With Forward Trunk Flexion

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 8, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
Postural abnormalities (PA) negatively affecting the axial system are part of the symptoms of Parkinson's disease (PD). They occur in more than 20% of patients with PD especially in more advanced stages of the disease, contribute significantly to patient disability, affect respiratory functions, and reduce quality of life. Eighty-five percent of patients with forward trunk flexion (FTF) reported difficulties with swallowing (dysphagia), shortness of breath, and drooling. Previous studies in patients with PD also identified cough disorders (dystussia). Since cough and properly functioning swallowing are key mechanisms for airway protection, impairments in these functions lead to a higher risk of aspiration. The seriousness of this problem is clearly confirmed by the fact that aspiration pneumonia is the leading cause of death in patients with PD. Among non-pharmacological interventions for airway protection, expiratory muscle strength training (EMST) has been shown to be beneficial in patients with PD. Recent randomized controlled studies demonstrated a significant effect of EMST on dysphagia, dystussia, drooling, and dysarthria in patients with PD. However, the literature lacks data on the effect of EMST on dystussia in patients with PD and FTF, who, according to previous research, are also affected by restrictive ventilatory impairment, which negatively affects respiratory capacity and, in particular, cough strength. The aim of this study is to evaluate the effect of EMST on cough, swallowing, respiratory muscle strength, and drooling in patients with PD and forward trunk flexion.
Trial Details
NCT Number NCT07268703
Lead Sponsor General University Hospital, Prague
Conditions Parkinson's Disease
Enrollment 28 participants
Start Date 2025-12
Primary Completion 2026-03 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2025-12-08